Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Elizabeth I, Buchbinder"'
Autor:
David Liu, F Stephen Hodi, Rizwan Haq, Anita Giobbie-Hurder, Ann W Silk, Patrick A Ott, Tamara A Sussman, Elizabeth I Buchbinder, Anna K Maloney, Nikita Katukota, Miklos C Fogarasi, Megan Insco
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 8 (2024)
Background The combination of ipilimumab and nivolumab is a highly effective treatment for metastatic cutaneous melanoma. However, immune-related adverse events (irAEs) are common, often necessitating treatment interruption and the use of immunosuppr
Externí odkaz:
https://doaj.org/article/4034db27552e463dbba1b096428e2377
Autor:
Costantine Albany, Andrea Pirzkall, Michael Chisamore, Jennifer Visich, Elizabeth I Buchbinder, Xiaohan Liu, David R Spigel, Kelly D Moynihan, Christopher DelNagro, Matt Axt, Mark Sayles
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d71c8f8460c0414cb01afc953fb43ffa
Autor:
Michael Manos, Arlene Sharpe, F Stephen Hodi, Joanna Baginska, Elizabeth I Buchbinder, Marta Holovatska, Kelly P Burke, Taras M Chicz, Julia Huezo, Duck Kyun Yoo, Fnu Keerti, Caihong Bi, Ryan McNamara, Duane Wesemann
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/216f6e7a14f54a00b8757718e59a3aee
Autor:
Omid Hamid, Diwakar Davar, Keisuke Shirai, Benjamin Izar, Charlotte E Ariyan, Michael K Wong, Jason J Luke, Janis M Taube, Anna C Pavlick, Meghan J Mooradian, Douglas B Johnson, Hussein A Tawbi, Tara C Mitchell, Ryan J Sullivan, April KS Salama, Krista M Rubin, Elizabeth I Buchbinder, Sarah A Weiss, Tina J Hieken, Geoffrey T Gibney, Rajan P Kulkarni, J Keith Tolley, Caressa Valdueza
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regi
Externí odkaz:
https://doaj.org/article/f4721e0504094c6083b6710589696855
Autor:
Jennifer E. Yeh, MD, PhD, Marilyn T. Wan, MBChB, MPH, Allireza Alloo, MD, Nageatte Ibrahim, MD, Patrick A. Ott, MD, PhD, Elizabeth I. Buchbinder, MD, Jennifer Y. Lin, MD
Publikováno v:
JAAD Case Reports, Vol 27, Iss , Pp 162-166 (2022)
Externí odkaz:
https://doaj.org/article/61a899a064ef46b1bfe0e0024ac4aba0
Autor:
Elizabeth I. Buchbinder, Jason L. Weirather, Michael Manos, Brian J. Quattrochi, Lynette M. Sholl, Ryan C. Brennick, Peter Bowling, Nancy Bailey, Lisa Magarace, Patrick A. Ott, Rizwan Haq, Benjamin Izar, Anita Giobbie‐Hurder, F. Stephen Hodi
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2627-2635 (2021)
Abstract Mucosal melanoma is a rare form of melanoma which arises from melanocytes in the mucosal membranes and can be effectively treated with immune checkpoint blockade (ICB). However, response rates in mucosal melanoma are lower than those observe
Externí odkaz:
https://doaj.org/article/24cb2e96d164402e9d316cff9ef36d9a
Autor:
Mariano Severgnini, Rizwan Haq, Anita Giobbie-Hurder, Scott J Rodig, Patrick A Ott, Evisa Gjini, Ryan J Sullivan, Donald P Lawrence, Matthew Nazzaro, Kathleen L Pfaff, Jacquelyn O Wolff, Elizabeth I Buchbinder
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/209a1d9fbce1433f83f364f311d116e0
Autor:
Elizabeth I. Buchbinder, Kathleen L. Pfaff, Madison M. Turner, Michael Manos, Olivia Ouyang, Patrick A. Ott, Anita Giobbie-Hurder, Scott J. Rodig, F. Stephen Hodi
Publikováno v:
Journal of Immunotherapy. 46:192-196
Autor:
Joseph M. Unger, Amy Darke, Megan Othus, Thach-Giao Truong, Nikhil Khushalani, Kari Kendra, Karl D. Lewis, Bryan Faller, Pauline Funchain, Elizabeth I. Buchbinder, Ahmad A. Tarhini, John M. Kirkwood, Elad Sharon, Vernon Sondak, Samantha R. Guild, Kenneth Grossmann, Antoni Ribas, Sapna P. Patel
Publikováno v:
JAMA oncology.
ImportanceA key issue for the adjuvant treatment of patients with melanoma is the assessment of the effect of treatment on relapse, survival, and quality of life (QOL).ObjectiveTo compare QOL in patients with resected melanoma at high risk for relaps
Autor:
Girish S. Naik, Sushrut S. Waikar, Alistair E. W. Johnson, Elizabeth I. Buchbinder, Rizwan Haq, F. Stephen Hodi, Jonathan D. Schoenfeld, Patrick A. Ott
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-17 (2019)
Abstract Background A male gender driven obesity paradox (improved survival for overweight/obese patients compared to normal weight) was recently shown in melanoma in the context of checkpoint inhibition (anti-PD-1/anti-CTLA4 monotherapy) in a pooled
Externí odkaz:
https://doaj.org/article/93d4682beb6d45b1ac4ee1d66abb75d5